Your Messages Inbox
Most Viewed Abstracts
1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 2. Omega-3 fatty acids for bipolar disorder 3. Is folic acid good for everyone 4. ACS Releases Guidelines for HPV Vaccination 5. Vitamin D - A review Free full text
Your Article Summary
See Latest ArticlesEpidermal growth factor receptor tyrosine kinase inhibitors: similar but different
Anti-Cancer Drugs, 10/19/09
Rukazenkov Y et al. – The authors hypothesize that gefitinib is used and is effective at a dose below the maximum tolerated dose as it accumulates in tumour tissue, thus providing the concentration needed at its target to achieve effective epidermal growth factor receptor inhibition in the tumour while causing less skin toxicity than erlotinib; therefore, skin rash is not a useful predictive factor for efficacy with gefitinib.
Related Articles
Eruptive Keratoacanthoma-Type Squamous Cell Carcinomas in Patients Taking Sorafenib for the Treatment of Solid Tumors
Dermatologic Surgery, 11/17/09
Relevance Score: 80%
Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia
Haematologica, 10/21/09
Relevance Score: 79%
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
Journal of Clinical Oncology, 10/16/09
Relevance Score: 79%
Small, Mobile Fc[epsilon]RI Receptor Aggregates Are Signaling Competent
Immunity, 10/01/09
Relevance Score: 79%
Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas
Modern Pathology, 10/28/09
Relevance Score: 78%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting
Internal Medicine Journal, 03/19/10
Anticancer effects of CAMEL peptide
Laboratory Investigation, 03/19/10
High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
British Journal of Haematology, 03/19/10
Sponsor
Article Search
Sponsor
Sponsor